Effectiveness of atorvastatin for reducing low-density lipoprotein cholesterol to national cholesterol education program treatment goals

American Journal of Cardiology

Volumn 80, Issue 3, 1997, Pages 347-348

  Davidson, Michael H ^a,b,c,d,e,f   Naworcki, James W ^a,b,c,d,e,f   Weiss, Stuart R ^a,b,c,d,e,f   Schwartz, Sherwyn L ^a,b,c,d,e,f   Lupien, Paul J ^a,b,c,d,e,f   Jones, Peter H ^a,b,c,d,e,f   Haber, Harry E ^a,b,c,d,e,f   Black, Donald M ^a,b,c,d,e,f  

^a RADIANT RESEARCH   (United States)

^b PFIZER INC   (United States)

^c S Diego Endocr and Medical Clinic   (United States)

^d Diabetes and Glandular Disease Clinic   (United States)

^e Lipid Research Center   (Canada)

^f BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CORONARY ARTERY DISEASE; COUNSELING; DIETARY INTAKE; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; HEPTANOIC ACIDS; HUMANS; MALE; MIDDLE AGED; PYRROLES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0030877713     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00360-3     Document Type: Article

References (5)

1. National Cholesterol Education Program: Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation. 89:1994;1329-1445.
2. Forrester JS, Bairey CN, Bush TL, Cohn JN, Hunninghake DB, Parthasarathy S, Superko HR. Task Force 4. Efficacy of risk factor management: 27th Bethesda Conference. Matching the intensity of risk factor management with the hazard for coronary disease events. J Am Coll Cardiol. 27:1996;964-1047.
3. Marcelino JJ, Feingold KR. Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. Am J Med. 100:1996;605-610.
4. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien P-J, Jones PH, Haber HE, Black DM. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol. 15:1995;678-682.
5. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 275:1996;128-133.